AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 12 min read$ABBV

RINVOQ Drives Continued Skin Repigmentation Through Week 76 In AbbVie Studies

AbbVie presented long-term data from Phase 3 studies showing continued facial and total-body repigmentation with RINVOQ in non-segmental vitiligo patients through Week 76. The safety profile remained consistent. The company also reported early data supporting RINVOQ's combination with NB-UVB phototherapy. ABBV stock is currently trading at $259.87, down 0.68%.

Original reporting
rttnews.com
Published Oct 1, 2026, 5:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 5:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
RINVOQ Drives Continued Skin Repigmentation Through Week 76 In AbbVie Studies — source image
Source · rttnews.com
Decision brief

The 30-second read

$ABBVBullishMed
01

Why it matters

Positive efficacy data could expand market adoption and support future label extensions, modestly boosting ABBV’s valuation.

02

Market read

First‑report Phase 3 data for a major biotech; likely to influence short‑term price and sector sentiment.

03

What to watch

Reimbursement pathways and insurance coverage for vitiligo treatments could limit commercial upside.

Relevance 8/10Novelty 8/10Timing: post‑release today

Background

AbbVie’s RINVOQ is already approved for vitiligo in the EU; the new long‑term data extend efficacy insights to Week 76.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

AbbVie presented new Phase 3 long‑term data showing increased facial and total‑body repigmentation through Week 76 for RINVOQ in vitiligo patients.

Expected impact

slight upward pressure as investors price in expanded label potential

Evidence & confidence

Phase 3 results are a primary disclosure for a large biotech; positive efficacy trends typically boost sentiment.

Market effects

Sector

Strengthens the dermatology/autoimmune therapeutic segment and may spur competitor R&D activity.

Regional

U.S. biotech sector could see modest gains on the back of the data.

Global

Potentially influences global investors tracking JAK‑inhibitor pipelines.

Counterpoint

What could challenge this read

If safety concerns or pricing issues emerge, the data may not translate into meaningful sales.

Key entities

  • company
    AbbVie

    US‑listed biopharma presenting the trial results.

  • drug
    RINVOQ (upadacitinib)

    Selective JAK inhibitor under study for vitiligo.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 1
$ABBVMedAI 8/10

AbbVie's Rinvoq Shows Promise in Vitiligo Trials, ABBV Stock Hig

AbbVie (ABBV) reported positive phase 3 trial results for Rinvoq in treating non-segmental vitiligo, with sustained repigmentation through week 76. The company filed for regulatory approvals, with an FDA decision expected in Q4 2026. AbbVie offers a 2.58% dividend yield but has a high payout ratio of 85%, raising concerns about dividend sustainability. The stock is trading 17.7% above its GF Value™ of $221.40.

gurufocus.com3 min
OCT 1
$ABBVMed

AbbVie gets US antitrust case over Humira trimmed

AbbVie won a partial dismissal in a US antitrust case over Humira, with a judge ruling that plaintiffs cannot seek damages as indirect purchasers. However, claims for injunctive relief were maintained, as the judge found it plausible that AbbVie's actions substantially foreclosed competitors. The case involves agreements with pharmacy benefit managers to favor Humira on formularies.

mlex.com1 min
OCT 1
$ABBVMedAI 8/10

AbbVie long-term data buoys Rinvoq for vitiligo

AbbVie's phase 3 studies show Rinvoq (upadacitinib) improved facial and total body repigmentation in vitiligo patients at week 76. Viti-Up-1 reported 55.1% and 42.5% reductions, while Viti-Up-2 reported 47.4% and 40.1%. AbbVie seeks FDA and EMA approval, with a decision expected in Q4. Rinvoq gained EU approval in July.

tradingview.com2 min
OCT 1
$ABBVMed

AbbVie reports long-term vitiligo data for RINVOQ at EADV

AbbVie (NYSE:ABBV) presented Phase 3 study data at the 2026 EADV Congress, showing improved repigmentation in vitiligo patients treated with RINVOQ through 76 weeks. The data indicated increased facial and total body repigmentation. Combining RINVOQ with phototherapy showed higher response rates. RINVOQ is approved in the EU for vitiligo and is under FDA review in the U.S.

investing.com2 min
OCT 1
$ABBVMed

AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo

AbbVie presented Phase 3 data showing RINVOQ's continued repigmentation benefits in non-segmental vitiligo through 76 weeks, with additional improvements when combined with NB-UVB phototherapy. Presented at the 2026 EADV Congress, the findings support RINVOQ's long-term use and potential combination therapies. RINVOQ is approved in the EU for vitiligo and under U.S. review.

news.abbvie.com2 min
SEP 30
$ABBVMedAI 8/10

AbbVie Reveals Positive Data for Eczema and Weight Loss Candidates

AbbVie (NYSE:ABBV) reported positive Phase 2 data for zumilokibart in treating atopic dermatitis, showing significant skin clearance and itch reduction. It also presented Phase 1 results for ABBV-295, its weight-loss candidate, with dose-dependent weight reductions of -7.8% to -9.8% over 12-13 weeks. ABBV shares were up 0.16% to $263.71 at the time of publication.

benzinga.com2 min